Buy Tasipimidine (USANTooltip) Cas 1465908-70-6
Tasipimidine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an α2-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs.[1][4] It is also under development for the treatment of insomnia in humans.[2][3][5] The drug is used as an oral solution in dogs,[1] whereas its route of administration for humans is unspecified.[3]
The drug acts as a potent and selective full agonist of the human α2A-adrenergic receptor.[2] Conversely, it is a much weaker agonist of the rodent α2B–, α2C–, and α2D-adrenergic receptors.[2] In addition, it shows only low affinity for α1-adrenergic receptors, where it appears to act as a partial agonist.[2] Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals.[2]
Tasipimidine is under development for use in humans by Orion Corporation.[3][5] As of October 2024, it is in phase 2 clinical trials for this indication.[3][5] The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported.[3] It has reached phase 1 trials for psychiatric disorders.[3] Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.[1]
Reviews
There are no reviews yet.